13June

Victoza® significantly reduced the risk of major cardiovascular events and death ... Read more

13June

Faster-acting insulin aspart showed a statistically significant reduction in HbA ... Read more

12June

Semaglutide demonstrated superior improvements in glycaemic control vs sitaglipt ... Read more

11June

Tresiba® (insulin degludec injection U-100) demonstrated significantly lower rat ... Read more

20June

Novo Nordisk A/S - Share repurchase programme ... Read more

13June

Novo Nordisk A/S - Share repurchase programme ... Read more

06June

Novo Nordisk A/S - Share repurchase programme ... Read more

30May

Novo Nordisk A/S - Share repurchase programme ... Read more

01July

Silent period,

05August

Financial statement for the first six months of 2016,

05August

Interim-dividend decleration,

08August

Q2 roadshow Europe,

 

 

 

Investors

 
Share information


Take an advanced view of the Novo Nordisk share

 
ADA 2016 investor event


Access the webcast for the ADA investor presentation

 
Q1 financial results


Access the Q1 material



Novo Nordisk at a glance


Private shareholders


See relevant content for private investors



IR material


Download relevant Investor Relations material



Contacts



Subscriptions


Sign up to receive company announcements.



Annual Report 2015


Download the Novo Nordisk Annual Report 2015